Research work · 2026
Blinatumomab
CDA-AMC
Canadian Journal of Health Technologies
Abstract
Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial drug plans and cancer agencies. This review assesses blinatumomab, 38.5 mcg/vial, lyophilized powder for solution, IV infusion. Indication under consideration for reimbursement: in combination with a TKI for the first-line treatment of Ph-positive ALL in adult and pediatric patients.